InMed Pharmaceuticals (INM) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
InMed Pharmaceuticals has bolstered its patent portfolio by securing three new U.S. patents, enhancing the protection and commercial viability of its innovative drug candidates for conditions with high unmet medical needs. These patents cover a range of areas, including the treatment of epidermolysis bullosa, a biosynthesis manufacturing process, and an ocular drug delivery formulation. This advancement reflects the company’s ongoing commitment to advancing its pipeline of proprietary small molecule drugs for a variety of serious health conditions.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
